Pipeline

BIAL’s medicines are already making a real difference to the lives of people all over the world. We are focused on neurosciences and cardiovascular areas.

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed

BIA 2-093 - Eslicarbazepine Ac. <div>Epilepsy - Adjunct</div>
100%
BIA 2-093 - Eslicarbazepine Ac. <div>Epilepsy - Paediatric</div>
100%
BIA 2-093 - Eslicarbazepine Ac. <div>Epilepsy - Monotherapy</div>
100%
BIA 5-1058 <div>Pulmonary Arterial Hypertension</div>
42%
BIA 9-1067 - Opicapone <div>Parkinson’s Disease</div>
100%
BIA 12 <div>Ophtalmology</div>
20%
BIA 19 <div>CNS</div>
20%
BIA 21 <div>Cardiovascular</div>
10%
BIA 23 <div>CNS</div>
2%
BIA 24 <div>CNS</div>
5%
BIA 25 <div>CNS</div>
5%
BIA 26 <div>CNS</div>
2%
BIA 27 <div>CNS</div>
2%
BIA 28-6156 <div>Parkinson’s Disease (GBA mutations)</div>
25%